Skip to content
Low‐dose gemcitabine plus nab‐paclitaxel <i>versus</i> standard‐dose gemcitabine plus nab‐paclitaxel in elderly patients with metastatic pancreatic cancer: A randomized Phase <scp>II</scp> trial — Hajime Imai (2023) | RDL Network